Division of Gynecologic Oncology, University of Alabama at Birmingham, United States of America.
Department of Obstetrics & Gynecology, University of Alabama at Birmingham, United States of America.
Gynecol Oncol. 2019 May;153(2):242-247. doi: 10.1016/j.ygyno.2019.03.001. Epub 2019 Mar 6.
To compare the perioperative morbidity and survival between abdominal radical hysterectomy (ARH) and robotic radical hysterectomy (RRH).
A retrospective cohort of patients undergoing radical hysterectomy for cervical cancer from 2010 to 2016 was identified. Patients with stage IB1 cervical cancer were included and were grouped by ARH vs. RRH. Tumor characteristics, perioperative complications, recurrence rate, progression-free survival (PFS), and overall survival (OS) were compared between groups.
105 patients were identified; 56 underwent ARH and 49 underwent RRH. Those who had ARH were more likely to have lesions that were ≥2 cm (62% vs. 39%, p = 0.02) and that were higher grade (p = 0.048). Other tumor characteristics were similar between groups. There was no difference in perioperative complication rates between groups. Additionally, there were no differences in recurrence risk (RR) (14% vs. 24%, p = 0.22), progression-free survival (PFS) (p = 0.28), or overall survival (OS) (p = 0.16). However, in those with tumors ≥2 cm there was a higher risk of recurrence in the overall cohort (30% vs. 8%, p = 0.006), and a shorter PFS in the RRH group (HR 0.31, p = 0.04). On multivariate analysis patients that underwent ARH or had tumors < 2 cm had a lower likelihood of recurrence (HR 0.38, p = 0.04; HR 0.175, p = 0.002) and death (HR 0.21, p = 0.029; HR 0.15, p = 0.02).
Perioperative morbidity was similar between those undergoing ARH vs. RRH for IB1 cervical cancer. Patients with tumors ≥ 2 cm undergoing RRH had a shorter PFS compared to ARH. On multivariate analysis, RRH and tumor size ≥ 2 cm were independently associated with recurrence and death in this population.
比较腹式根治性子宫切除术(ARH)和机器人根治性子宫切除术(RRH)的围手术期发病率和生存率。
回顾性分析 2010 年至 2016 年间接受根治性子宫切除术治疗宫颈癌的患者队列。纳入 I B1 期宫颈癌患者,并按 ARH 与 RRH 进行分组。比较两组间肿瘤特征、围手术期并发症、复发率、无进展生存率(PFS)和总生存率(OS)。
共纳入 105 例患者,其中 56 例行 ARH,49 例行 RRH。行 ARH 的患者肿瘤更大(≥2cm,62% vs. 39%,p=0.02)、分级更高(p=0.048)的可能性更高。两组间其他肿瘤特征相似。两组间围手术期并发症发生率无差异。此外,两组间复发风险(RR)(14% vs. 24%,p=0.22)、无进展生存率(PFS)(p=0.28)或总生存率(OS)(p=0.16)无差异。然而,在所有患者中,肿瘤≥2cm 者的总体复发风险更高(30% vs. 8%,p=0.006),RRH 组的 PFS 更短(HR 0.31,p=0.04)。多因素分析显示,行 ARH 或肿瘤<2cm 的患者复发率较低(HR 0.38,p=0.04;HR 0.175,p=0.002)和死亡率较低(HR 0.21,p=0.029;HR 0.15,p=0.02)。
IB1 期宫颈癌患者行 ARH 与 RRH 的围手术期发病率相似。RRH 治疗肿瘤≥2cm 的患者 PFS 较 ARH 更短。多因素分析显示,RRH 和肿瘤大小≥2cm 与该人群的复发和死亡独立相关。